The outcome of this litigation as well as the effects of the IRA on the pharmaceutical industry cannot yet be fully determined but is likely to be significant. Additional drug pricing proposals could appear in future legislation.
All entries for: Metabolic Diseases
May 20, 2025
Prime Medicine
Discontinued Research, Layoffs
Cambridge, MA
201-500 employees
As part of a strategic restructuring that includes deprioritizing its chronic granulomatous disease (CGD) programs, Prime Medicine is cutting about 25% of its staff and saying goodbye to its CEO, who resigned, the company announced May 19. The Cambridge, Massachusetts–based biotech had 214 full-time employees as of Dec. 31, 2024, according to an SEC filing, meaning the layoffs could affect about 54 people.
Disease Area: Hematology, Immune Diseases, Metabolic Diseases, Multiple, Respiratory Diseases
Drug Type: Biologic
May 14, 2025
Maze Therapeutics
Negative Outlook
South San Francisco, CA
51-200 employees
Manufacturers that fail to comply with the Inflation Reduction Act may be subject to various penalties, some significant, including civil monetary penalties. These provisions are taking effect progressively starting in 2023, although they may be subject to legal challenges. For example, the provisions related to the negotiation of selling prices of high-expenditure single-source drugs and biologics have been challenged in multiple lawsuits. Thus, it is unclear how the Inflation Reduction Act will be implemented but it will likely have a significant impact on the pharmaceutical industry and the pricing of our products and therapeutic candidates. The adoption of restrictive price controls in new jurisdictions, more restrictive controls in existing jurisdictions or the failure to obtain or maintain timely or adequate pricing could also adversely impact revenue. We expect pricing pressures will continue globally.
Disease Area: Chronic Disease, Metabolic Diseases, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Small Molecule
May 12, 2025
Mestera
Neutral Outlook
New York, NY
1-50 employees
The implementation of the IRA is currently subject to ongoing litigation that challenges the constitutionality of the IRA’s drug price negotiation program provisions. The outcome of this litigation as well as the effects of the IRA on the pharmaceutical industry cannot yet be fully determined but is likely to be significant.
Disease Area: Metabolic Diseases
Drug Type: Biologic, Small Molecule
May 12, 2025
RallyBio
Layoffs
New Haven, CT
1-50 employees
Rallybio is laying off nine employees, about 40% of its total headcount, as it reels from the loss of its lead asset, the biotech announced in its first-quarter earnings report May 8.
Disease Area: Hematology, Metabolic Diseases, Multiple, Rare Diseases
Drug Type: Biologic, Small Molecule
May 8, 2025
Korro Bio
Layoffs
Cambridge, MA
51-200 employees
In a bid to keep its business afloat into 2027, Korro Bio is streamlining its operations, a move that will involve a 20% workforce reduction, the biotech announced Wednesday alongside its Q1 business report. The layoffs, which will cost Korro $1.2 million in one-time payments, will help the biotech advance its assets to “key value inflection points.” In particular, Korro aims to complete its ongoing Phase I/IIa REWRITE trial, which is testing its investigational RNA-editing oligonucleotide KRRO-110 in alpha-1 antitrypsin deficiency. The company expects to wrap up REWRITE in 2026.
Disease Area: Gastrointestinal, Metabolic Diseases, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
May 7, 2025
NGM Bio
Layoffs
San Mateo County, CA
51-200 employees
NGM Bio is cutting 85 employees, according to a San Francisco WARN Notice from last week. The layoffs, which will affect staff at its San Mateo County location, will take effect on June 30. The workforce reduction affects 75% of the workforce, Fierce Biotech reported May 12
Disease Area: Gastrointestinal, Metabolic Diseases, Multiple, Oncology, Rare Diseases
Drug Type: Biologic
May 6, 2025
BioAge Labs
Negative Outlook
Richmond, CA
51-200 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry and the pricing of BGE-102 or any future product candidates.
Disease Area: Metabolic Diseases
Drug Type: Small Molecule
May 1, 2025
Entrada Therapeutics
Layoffs
Boston, MA
51-200 employees
As it focuses resources on Duchenne muscular dystrophy (DMD) clinical candidates and key preclinical programs, Entrada Therapeutics disclosed layoff and hiring plans in an April 29 SEC filing. Although the biotech will hire to support a planned global clinical trial for Duchenne, it will also reduce research staff, affecting about 20% of its workforce.
Disease Area: Metabolic Diseases, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
May 1, 2025
Ardelyx
Neutral Outlook
Waltham, MA
201-500 employees
While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant
Disease Area: Cardiology, Chronic Disease, Gastrointestinal, Metabolic Diseases, Multiple
Drug Type: Small Molecule